Synexus expands

pharmafile | July 30, 2009 | News story | Research and Development CRO, Synexus 

CRO Synexus has doubled its head office capacity as it continues to grow across the UK, Central and Eastern Europe, India and South Africa.

The move into the new, modern head office premises in Chorley, Manchester, includes taking over an adjacent building and completely re-vamping the existing offices.

Part of the re-modelling process includes a new state-of-the-art Cognos IT system developed in partnership with IBM and promises to deliver significant benefits to Synexus clients right across the clinical study lifecycle.

The head office, from which Synexus manages its global network of 16 dedicated research centres, now employs some 60 staff who have helped increase the company's turnover by 60% in 2008 and are forecasting a similar increase in 2009.

Michael Fort, chief executive, said: "We are in the enviable position of continuing to enjoy robust growth during what for many are tough times. The increased capacity at our head office will support our growth and ensure we remain efficient.

"It's important to make sure our teams at head office are working in the right environment and also that we have room to grow – the re-vamped and extended offices do just that. Synexus remains a lean and efficient organisation and one which takes great pride in delivering not only first class results but also innovative solutions."

Synexus is also developing its presence in Central and Eastern Europe, having recently opened regional office in Hungary headed up by Dr Christian Tueni. The company has sites in Poland, Hungary and Bulgaria and several more are planned.

Related Content

Science image

Drug development contracts: can lessons be learned from healthcare delivery?

There is a very good question to ask at the beginning of every project: “What …

Covance image

LabCorp buys Covance for $6.1 billion

US medical diagnostics firm LabCorp has entered the drug development business via a $6.1 billion …

Parexel acquires ClinIntel for trial supply services

Clinical research organisation Parexel has acquired all of the outstanding equity securities of privately-owned ClinIntel, …

Latest content